 fospropofol disodium |
| Lusedra |
Pharmaceutical
company:
Eisai Inc.
www.eisai.com |
Pharmacologic classification: phenol derivative
Therapeutic classification: sedative-hypnotic
Pregnancy risk category: B
AVAILABLE FORMS
Injection: 35 mg/ml single-use vial
INDICATIONS AND DOSAGES
Monitored anesthesia care—
Adults younger than age 65 classified as American Society of Anesthesiologists (ASA) Physical Status (PS) category 1 or 2: Initially, 6.5 mg/kg I.V. followed by 1.6 mg/kg I.V. as needed, but no more frequently than every 4 minutes, to achieve desired level of sedation. Dosage is limited by weight bounds. Patients weighing more than 90 kg (198 lb) should be dosed as if they weigh 90 kg; patients weighing less than 60 kg (132 lb) should be dosed as if they weigh 60 kg.
ADJUST-A-DOSE: In adults age 65 and older or those with ASA PS category 3 or 4, give initial and supplemental doses of 75% of the standard dose.
CONTRAINDICATIONS AND CAUTIONS
Use cautiously in patients who are hemodynamically unstable. Avoid using in breast-feeding women; drug appears in breast milk.
INTERACTIONS
Drug-drug.
Opioids (alfentanil, fentanyl, meperidine, morphine) and sedatives (barbiturates, benzodiazepines, chloral hydrate, droperidol): May further increase sedative effects and further decrease blood pressure, cardiac output, and respiratory status.
ADVERSE REACTIONS
CNS: headache, paresthesia.
CV: hypotension.
GI: nausea, vomiting.
Respiratory: hypoxemia.
Skin: pruritus.
Reactions may be common, uncommon, life-threatening,
or COMMON AND LIFE-THREATENING.
|
